Index
Module 7 • Infectious Diseases
Infectious Diseases II
93%
Core Content
Infectious Diseases II
Gabrielle Gibson ~3 min read Module 7 of 20
71
/ 76

Infectious Diseases II

importance of combination therapy. Clin Infect Dis.

2012;55(7):943-950. https://doi.org/10.1093/cid/cis588

van Duin D, Bonomo RA. Ceftazidime/avibactam and

ceftolozane/tazobactam: second-generation ฮฒ-lactam/

ฮฒ-lactamase inhibitor combinations. Clin Infect Dis.

2016;63(2):234-241. https://doi.org/10.1093/cid/ciw243

van Duin D, Cober ED, Richter SS, et al. Tigecycline

therapy for carbapenem-resistant Klebsiella pneumoniae

(CRKP) bacteriuria leads to tigecycline resistance. Clin

Microbiol Infect. 2014;20(12):O1117-O1120. https://doi.

org/10.1111/1469-0691.12714

van Duin D, Lok JJ, Earley M, et al. Colistin versus

ceftazidime-avibactam in the treatment of infections

due to carbapenem-resistant Enterobacteriaceae. Clin

Infect Dis. 2018;66(2):163-171. https://doi.org/10.1093/

cid/cix783

Weiner-Lastinger LM, Abner S, Edwards JR, et al.

Antimicrobial-resistant pathogens associated with adult

healthcare-associated infections: summary of data

reported to the National Healthcare Safety Network,

2015-2017. Infect Control Hosp Epidemiol. 2020;41(1):1-

18. https://doi.org/10.1017/ice.2019.296

Wu JY, Srinivas P, Pogue JM. Cefiderocol: a novel agent

for the management of multidrug-resistant gram-nega-

tive organisms. Infect Dis Ther. 2020;9(1):17-40. https://

doi.org/10.1007/s40121-020-00286-6

Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et

al. Effect and safety of meropenem-vaborbactam versus

best-available therapy in patients with carbapenem-

resistant Enterobacteriaceae infections: the TANGO II

randomized clinical trial. Infect Dis Ther. 2018;7(4):439-

455. https://doi.org/10.1007/s40121-018-0214-1

Wunderink RG, Niederman MS, Kollef MH, et al.

Linezolid

in

methicillin-resistant

Staphylococcus

aureus nosocomial pneumonia: a randomized, con-

trolled study. Clin Infect Dis. 2012;54(5):621-629. https://

doi.org/10.1093/cid/cir895

Wunderink RG, Roquilly A, Croce M, et al. A

phase 3, randomized, double-blind study compar-

ing tedizolid phosphate and linezolid for treatment of

ventilated gram-positive hospital-acquired or ventila-

tor-associated bacterial pneumonia. Clin Infect Dis.

2021;73(3):e710-e718. https://doi.org/10.1093/cid/ciab032

Immunocompromised Patients

Baden LR, Swaminathan S, Angarone M, et al.

Prevention and treatment of cancer-related infections,

version 2.2016, NCCN clinical practice guidelines in

oncology. J Natl Compr Canc Netw. 2016;14(7):882-913.

https://doi.org/10.6004/jnccn.2016.0093

Fishman JA. Infection in organ transplantation. Am J

Transplant. 2017;17(4):856-879. https://doi.org/10.1111/

ajt.14208

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical

practice guideline for the use of antimicrobial agents

in neutropenic patients with cancer: 2010 update by the

Infectious Diseases Society of America. Clin Infect Dis.

2011;52(4):e56-e93. https://doi.org/10.1093/cid/cir073

Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient man-

agement of fever and neutropenia in adults treated for

malignancy: American Society of Clinical Oncology and

Infectious Diseases Society of America clinical practice

guideline update. J Clin Oncol. 2018;36(14):1443-1453.

https://doi.org/10.1200/jco.2017.77.6211

HIV/AIDS in Critically Ill Patients

Barbier F, Mer M, Szychowiak P, et al. Management of

HIV-infected patients in the intensive care unit. Intensive

Care Med. 2020;46(2):329-342. https://doi.org/10.1007/

s00134-020-05945-3

Panel on Antiretroviral Guidelines for Adults and

Adolescents. Guidelines for the use of antiretrovi-

ral agents in HIV-1-infected adults and adolescents.

Department of Health and Human Services. https://clini-

calinfo.hiv.gov/sites/default/files/guidelines/documents/

adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf

Panel on Guidelines for the Prevention and Treatment

of Opportunistic Infections in Adults and Adolescents

with HIV. Guidelines for the prevention and treatment of

opportunistic infections in adults and adolescents with

HIV. National Institutes of Health, Centers for Disease

Control and Prevention, the HIV Medicine Association,

and the Infectious Diseases Society of America.

https://clinicalinfo.hiv.gov/sites/default/files/guidelines/

documents/adult-adolescent-oi/guidelines-adult-adoles-

cent-oi.pdf

Rosen MJ, Narasimhan M. Critical care of immuno-

compromised patients: human immunodeficiency virus.

Crit Care Med. 2006;34(9 suppl):S245-S250. https://doi.

org/10.1097/01.ccm.0000232491.15369.ab

HD Video Explanation โ€” Synchronized with PDF
Starts at: minute 70 Open on YouTube